Replies to post #128357 on Biotech Values

[NP1986]

I think if ruxolitinib were to be used strictly in the patient population eligible for COMFORT-I or COMFORT-II, it is ~60% of MF patients. If anything, the phase III trials enrolled a broader population than the phase I/II study.

It will be interesting to see what the long-term data from COMFORT-I and COMFORT-II look like. IIRC, the discontinuation rates reported at ASCO weren't as high as the NEJM letter suggests.

[eawolfie]

Here is what LS had to say as posted on yahoo
Leerink Swann reiterates an 'Outperform' on Incyte (NASDAQ: INCY), low/mid-$20's target valuation.

Leerink analyst says, "We believe INCY shares are trading down in response to an NEJM article by Dr. Ayalew Tefferi from the Mayo Clinic. The article discusses 51 patients with myelofibrosis treated with Ruxolitinib and notes a high drop-off rate and inconsistent durable effects. While on the surface this would appear to be problematic for Ruxolitinib's prospects, we note material omissions in the publication and are actually surprised the NEJM would publish such analysis as, in our view, it is deficient. We believe the analysis mischaracterizes Ruxolitinib's profile."